Ana Lleo

List of Publications by Citations

Source: https://exaly.com/author-pdf/2663564/ana-lleo-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

134 6,499 44 78 g-index

167 8,137 7.1 5.6 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
134	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1522-1534	59.2	913
133	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010 , 42, 658-60	36.3	337
132	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <i>Gastroenterology</i> , 2014 , 147, 1338-49.e5; quiz e15	13.3	265
131	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015 , 149, 1804-1812.e4	13.3	235
130	The X chromosome and immune associated genes. <i>Journal of Autoimmunity</i> , 2012 , 38, J187-92	15.5	199
129	International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. <i>Nature Communications</i> , 2015 , 6, 8019	17.4	185
128	Definition of human autoimmunityautoantibodies versus autoimmune disease. <i>Autoimmunity Reviews</i> , 2010 , 9, A259-66	13.6	171
127	Primary biliary cirrhosis is associated with altered hepatic microRNA expression. <i>Journal of Autoimmunity</i> , 2009 , 32, 246-53	15.5	167
126	Apotopes and the biliary specificity of primary biliary cirrhosis. <i>Hepatology</i> , 2009 , 49, 871-9	11.2	158
125	Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis. <i>Hepatology</i> , 2010 , 52, 987-98	11.2	154
124	Is autoimmunity a matter of sex?. Autoimmunity Reviews, 2008, 7, 626-30	13.6	143
123	Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012 , 21, 5209-21	5.6	122
122	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016 , 65, 321-9	19.2	107
121	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 35, 436-42	15.5	103
120	Geoepidemiology, gender and autoimmune disease. <i>Autoimmunity Reviews</i> , 2012 , 11, A386-92	13.6	100
119	The consequences of apoptosis in autoimmunity. <i>Journal of Autoimmunity</i> , 2008 , 31, 257-62	15.5	98
118	Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. <i>Hepatology</i> , 2008 , 48, 1906-12	11.2	98

(2020-2012)

117	Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2012 , 55, 153-60	11.2	93
116	Interpreting serological tests in diagnosing autoimmune liver diseases. <i>Seminars in Liver Disease</i> , 2007 , 27, 161-72	7.3	87
115	Autophagy: highlighting a novel player in the autoimmunity scenario. <i>Journal of Autoimmunity</i> , 2007 , 29, 61-8	15.5	83
114	The immunological potential of galectin-1 and -3. <i>Autoimmunity Reviews</i> , 2009 , 8, 360-3	13.6	82
113	Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. <i>Scientific Reports</i> , 2016 , 6, 25906	4.9	82
112	Y chromosome loss in male patients with primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013 , 41, 87-91	15.5	73
111	Etiopathogenesis of primary biliary cirrhosis. World Journal of Gastroenterology, 2008, 14, 3328-37	5.6	72
110	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
109	DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis. <i>Clinical Epigenetics</i> , 2015 , 7, 61	7.7	66
108	Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. <i>Genes and Immunity</i> , 2012 , 13, 461-8	4.4	66
107	Primary biliary cholangitis: a comprehensive overview. <i>Hepatology International</i> , 2017 , 11, 485-499	8.8	65
106	Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. <i>Hepatology</i> , 2014 , 60, 1314-23	11.2	64
105	Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis. <i>Epigenetics</i> , 2011 , 6, 95-102	5.7	64
104	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <i>Clinical and Experimental Immunology</i> , 2016 , 185, 61-71	6.2	59
103	Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2010 , 35, 176-80	15.5	58
102	B cell depletion therapy exacerbates murine primary biliary cirrhosis. <i>Hepatology</i> , 2011 , 53, 527-35	11.2	56
101	Autoimmunity and Turner® syndrome. Autoimmunity Reviews, 2012, 11, A538-43	13.6	55
100	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. <i>Journal of Autoimmunity</i> , 2020 , 114, 102511	15.5	53

99	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <i>Journal of Autoimmunity</i> , 2013 , 46, 81-7	15.5	52
98	Innate immunity and primary biliary cirrhosis. Current Molecular Medicine, 2009, 9, 45-51	2.5	52
97	Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis. <i>Hepatology</i> , 2011 , 54, 196-203	11.2	48
96	The tumour microenvironment and immune milieu of cholangiocarcinoma. <i>Liver International</i> , 2019 , 39 Suppl 1, 63-78	7.9	47
95	X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma. <i>Clinical and Experimental Immunology</i> , 2012 , 169, 253-62	6.2	47
94	Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. <i>Journal of Autoimmunity</i> , 2012 , 38, J193-6	15.5	47
93	Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. <i>Hepatology</i> , 2013 , 57, 1498-508	11.2	46
92	Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. <i>Frontiers in Immunology</i> , 2014 , 5, 128	8.4	46
91	Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. <i>Genes and Immunity</i> , 2013 , 14, 179-86	4.4	44
90	HLA class II antigens associated with lupus nephritis in Italian SLE patients. <i>Human Immunology</i> , 2003 , 64, 462-8	2.3	44
89	Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. <i>American Journal of Physiology - Renal Physiology</i> , 2011 , 301, G623-33	5.1	41
88	Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. <i>Journal of Hepatology</i> , 2010 , 52, 712-7	13.4	40
87	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020 , 73, 453-455	13.4	40
86	Genetics and epigenetics of primary biliary cirrhosis. <i>Seminars in Liver Disease</i> , 2014 , 34, 255-64	7.3	35
85	Towards common denominators in primary biliary cirrhosis: the role of IL-12. <i>Journal of Hepatology</i> , 2012 , 56, 731-3	13.4	35
84	COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2366-2368.e3	6.9	35
83	Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	35
82	Primary biliary cholangitis. <i>Lancet, The</i> , 2020 , 396, 1915-1926	40	33

81	Role of liver biopsy in hepatocellular carcinoma. World Journal of Gastroenterology, 2019, 25, 6041-6052	25.6	33
80	Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review. <i>Liver Cancer</i> , 2020 , 9, 15-27	9.1	33
79	Common Variable Immunodeficiency and Liver Involvement. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 340-351	12.3	32
7 ⁸	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020 , 115, 1066-1074	0.7	31
77	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. <i>Clinical and Experimental Immunology</i> , 2011 , 165, 243-50	6.2	31
76	Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 310-317	3.3	29
75	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2076-2084	l.62	27
74	Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. <i>Nutrients</i> , 2019 , 11,	6.7	27
73	Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. <i>European Journal of Immunology</i> , 2014 , 44, 945-54	6.1	26
72	Advances in pharmacotherapy for primary biliary cirrhosis. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 633-43	4	25
71	Role of cholangiocytes in primary biliary cirrhosis. Seminars in Liver Disease, 2014, 34, 273-84	7.3	25
70	Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes. <i>Journal of Gastroenterology</i> , 2011 , 46 Suppl 1, 29-38	6.9	25
69	Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. <i>Cancers</i> , 2020 , 12,	6.6	25
68	Geoepidemiology, Genetic and Environmental Risk Factors for PBC. <i>Digestive Diseases</i> , 2015 , 33 Suppl 2, 94-101	3.2	24
67	Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. <i>Hepatology</i> , 2012 , 55, 1495-506	11.2	24
66	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. BMC Gastroenterology, 2012 , 12, 92	3	23
65	The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020 , 40, 34-48	7-3	23
64	Immunopathogenesis of primary biliary cirrhosis: an old wivesRtale. <i>Immunity and Ageing</i> , 2011 , 8, 12	9.7	22

63	The epigenetics of PBC: The link between genetic susceptibility and environment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016 , 40, 650-659	2.4	22
62	The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2015 , 47, 432-5	3.3	21
61	High mortality in COVID-19 patients with mild respiratory disease. <i>European Journal of Clinical Investigation</i> , 2020 , 50, e13314	4.6	21
60	High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 17	05:171	12 ²¹
59	Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. <i>Mediators of Inflammation</i> , 2015 , 2015, 436450	4.3	20
58	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019 , 51, 1074-1078	3.3	19
57	Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis. <i>PLoS ONE</i> , 2016 , 11, e0159612	3.7	19
56	The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. <i>Journal of Autoimmunity</i> , 2019 , 100, 17-26	15.5	18
55	Making Sense of Autoantibodies in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2016 , 20, 33-46	4.6	17
54	Apotopes and innate immune system: novel players in the primary biliary cirrhosis scenario. <i>Digestive and Liver Disease</i> , 2013 , 45, 630-6	3.3	17
53	Rapid automated diagnosis of primary hepatic tumour by mass spectrometry and artificial intelligence. <i>Liver International</i> , 2020 , 40, 3117-3124	7.9	17
52	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. <i>Immunobiology</i> , 2015 , 220, 1025-9	3.4	15
51	Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. <i>Cancers</i> , 2020 , 12,	6.6	14
50	Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2019 , 23, 2216-2224	3.3	13
49	The risk of liver cancer in autoimmune liver diseases. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919861914	5.4	13
48	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. <i>Frontiers in Oncology</i> , 2018 , 8, 181	5.3	11
47	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <i>Digestive and Liver Disease</i> , 2014 , 46, 363-8	3.3	11
46	Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 847-57	6.5	11

(2012-2018)

45	The impact of antiviral therapy on hepatocellular carcinoma epidemiology. <i>Hepatic Oncology</i> , 2018 , 5, HEP03	4	11	
44	Changes in the Epidemiology of Primary Biliary Cholangitis. <i>Clinics in Liver Disease</i> , 2018 , 22, 429-441	4.6	11	
43	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry <i>Journal of Hepatology</i> , 2021 ,	13.4	10	
42	Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4900-4918	5.6	10	
41	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , 2021 , 3, 100248	10.3	10	
40	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2021 , 160, 2483-2495.e26	13.3	9	
39	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021 , 75, 572-581	13.4	8	
38	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. <i>Journal of Leukocyte Biology</i> , 2020 , 108, 715-721	6.5	6	
37	Transcriptional Differences for COVID-19 Disease Map Genes between Males and Females Indicate a Different Basal Immunophenotype Relevant to the Disease. <i>Genes</i> , 2020 , 11,	4.2	5	
36	Postsustained Virological Response Management in Hepatitis C Patients. <i>Seminars in Liver Disease</i> , 2020 , 40, 233-239	7.3	4	
35	Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis. <i>Updates in Surgery</i> , 2020 , 72, 671-679	2.9	4	
34	Experimental liver models: From cell culture techniques to microfluidic organs-on-chip. <i>Liver International</i> , 2021 , 41, 1744-1761	7.9	4	
33	Human Defensin 2 in Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2017 , 8, e80	4.2	3	
32	Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma. <i>Updates in Surgery</i> , 2020 , 72, 413-421	2.9	3	
31	Is Liver Injury an Affordable Risk of Immune Checkpoint Inhibitor Therapy for Cancer?. <i>Gastroenterology</i> , 2018 , 155, 2021-2023	13.3	3	
30	Antimitochondrial Antibodies: from Bench to Bedside. <i>Clinical Reviews in Allergy and Immunology</i> , 2021 , 1	12.3	3	
29	Safety of vedolizumab in liver transplant recipients: A systematic review. <i>United European Gastroenterology Journal</i> , 2019 , 7, 875-880	5.3	2	
28	The X-factor in primary biliary cirrhosis: monosomy X and xenobiotics. <i>Autoimmunity Highlights</i> , 2012 , 3, 127-32	3.7	2	

27	New susceptibility loci for severe COVID-19 by detailed GWAS analysis in European populations		2
26	Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2021 , 3, 906-908	2.7	2
25	SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study. <i>Journal of Hepatology</i> , 2018 , 68, S86	13.4	2
24	Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases. <i>Vaccines</i> , 2022 , 10, 801	5.3	2
23	What Is an Autoantibody? 2014 , 13-20		1
22	Identifying medical professionals at risk for in-hospital COVID-19 infection: a snapshot during a "tsunami" highlighting unexpected risks. <i>Global Health & Medicine</i> , 2020 , 2, 235-239	2.4	1
21	Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 33,	2.2	1
20	Primary Biliary Cirrhosis and Autoimmune Cholangitis 2007 , 235-247		1
19	Transcriptional differences for COVID-19 Disease Map genes between males and females indicate a different basal immunophenotype relevant to the disease		1
18	Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?. <i>Hepatology</i> , 2020 , 72, 359-360	11.2	1
17	Directly acting antivirals are safe and effective in HCV positive patients aged 80 years and older: a multicenter real-life study. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 839-843	4.1	1
16	Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?. <i>Hepatology</i> , 2021 , 74, 2307	11.2	1
15	What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. <i>United European Gastroenterology Journal</i> , 2021 , 9, 787	5.3	1
14	Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2018 , 17, 570-574	2.1	1
13	Versatile Mass Spectrometry-Based Intraoperative Diagnosis of Liver Tumor in a Multiethnic Cohort. <i>Applied Sciences (Switzerland)</i> , 2022 , 12, 4244	2.6	1
12	Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization. <i>Applied Sciences (Switzerland)</i> , 2021 , 11, 9342	2.6	O
11	High prevalence of multidrug-resistant bacteria in patients with pyogenic liver abscess following liver cancer loco-regional treatments. <i>Liver International</i> , 2021 , 41, 1909-1912	7.9	0
10	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 558	-5 68	O

LIST OF PUBLICATIONS

9	Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. <i>Current Transplantation Reports</i> , 2019 , 6, 134-145	1.5
8	Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis. <i>Gastroenterology</i> , 2019 , 156, 1930-1931	13.3
7	Geoepidemiology and the Impact of Sex on Autoimmune Diseases 2017, 323-333	
6	The Epigenetics of Primary Biliary Cholangitis 2018 , 251-272	
5	Small and Large Bile Ducts Intrahepatic Cholangiocarcinoma Classification: A Preliminary Feature-Based Study. <i>Lecture Notes in Computer Science</i> , 2021 , 237-244	0.9
4	Direct-acting antivirals for chronic hepatitis C virus genotype 5 and 6 infections. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 5-6	18.8
3	No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals. <i>Liver International</i> , 2018 , 38, 2342-2342.	7.9
2	High prevalence of porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels <i>Liver International</i> , 2022 ,	7.9
1	Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges World Journal of Gastroenterology, 2022 , 28, 1430-1443	5.6